Observed responses for patients treated at the 40-µg/kg dose level
| . | Dose escalation/expansion (40 µg/kg), n (%) . | Treatment naive* (40 µg/kg), n (%) . | ||
|---|---|---|---|---|
| All treated (N = 18) . | Efficacy evaluable† (N = 17) . | All treated (N = 27) . | Efficacy evaluable† (N = 26) . | |
| CR | 2 (11) | 2 (12) | 6 (22) | 6 (23) |
| CRi | 3 (17) | 3 (18) | 9 (33) | 9 (35) |
| mLFS | 3 (17) | 3 (18) | 4 (15) | 4 (15) |
| Resistant disease | 9 (50) | 9 (53) | 7 (26) | 7 (27) |
| CRc rate (CR + CRi) | 5 (28) | 5 (29) | 15 (56) | 15 (58) |
| Blast clearance (CR+ CRi + mLFS) | 8 (44) | 8 (47) | 19 (70) | 19 (73) |
| . | Dose escalation/expansion (40 µg/kg), n (%) . | Treatment naive* (40 µg/kg), n (%) . | ||
|---|---|---|---|---|
| All treated (N = 18) . | Efficacy evaluable† (N = 17) . | All treated (N = 27) . | Efficacy evaluable† (N = 26) . | |
| CR | 2 (11) | 2 (12) | 6 (22) | 6 (23) |
| CRi | 3 (17) | 3 (18) | 9 (33) | 9 (35) |
| mLFS | 3 (17) | 3 (18) | 4 (15) | 4 (15) |
| Resistant disease | 9 (50) | 9 (53) | 7 (26) | 7 (27) |
| CRc rate (CR + CRi) | 5 (28) | 5 (29) | 15 (56) | 15 (58) |
| Blast clearance (CR+ CRi + mLFS) | 8 (44) | 8 (47) | 19 (70) | 19 (73) |